{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:21:33Z","timestamp":1755224493318,"version":"3.43.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with endocarditis often have comorbid injection substance use and are at risk for hepatitis C virus (HCV) infection. This population may encounter several significant barriers to treatment. To improve access to treatment, we developed an interdisciplinary collaboration between specialty pharmacy and the University of Kentucky endocarditis team and conducted a retrospective study evaluating treatment outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Beginning in September 2021, the endocarditis team worked with specialty pharmacy to connect inpatients with endocarditis and HCV to expedited treatment and coordinated outpatient follow-up. Study investigators then retrospectively reviewed data consisting of patient demographics and treatment outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between September 2021 and April 2024, 64 patients with infective endocarditis and HCV were identified (median age, 37 years; 41% female, 97% with a history of injection drug use). Upon discharge, 75% (48 of 64) initiated treatment. Treatment was completed in 69% (33 of 48) of these patients. The main reasons for discontinuation included loss to follow-up (n = 10) and medication side effects (n = 3). Sustained virologic response at 12 weeks was achieved in 42% (n = 20) of patients who initiated treatment and 31% of all patients. Among 22 patients with available laboratory results at 12 weeks posttreatment, 91% (n = 20) were HCV RNA negative.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite efforts promoting expedited treatment and interdisciplinary coordination of care, sustained virologic response rates for patients with endocarditis and HCV infection remained &amp;lt;40%. More research is required to determine if interventions such as starting therapy during inpatient stay or immediately upon discharge and dispensing the entire course of medication at once can improve treatment outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf431","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T06:42:28Z","timestamp":1753080148000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis C Treatment Outcomes for Patients With Infective Endocarditis Treated by an Interdisciplinary Team"],"prefix":"10.1093","volume":"12","author":[{"given":"Lauren","family":"McQuaide","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Kentucky , Lexington, Kentucky ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-2951","authenticated-orcid":false,"given":"Sami","family":"El-Dalati","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center , Lexington, Kentucky ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center , Lexington, Kentucky ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobbi Jo","family":"Stoner","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Kentucky , Lexington, Kentucky ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"2025081213375222800_ofaf431-B1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.idc.2020.06.004","article-title":"Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments","volume":"34","author":"Schranz","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2025081213375222800_ofaf431-B2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/ciac543","article-title":"Estimated number of people who inject drugs in the United States","volume":"76","author":"Bradley","year":"2023","journal-title":"Clin Infect Dis"},{"author":"Centers for Disease Control and Prevention. Hepatitis C surveillance 2021","key":"2025081213375222800_ofaf431-B3"},{"key":"2025081213375222800_ofaf431-B4","doi-asserted-by":"crossref","first-page":"e26136","DOI":"10.1002\/jia2.26136","article-title":"The path to hepatitis C elimination: who are we leaving behind and why?","volume":"26","author":"Rockstroh","year":"2023","journal-title":"J Int AIDS Soc"},{"year":"2024","author":"World Health Organization. Global health sector strategies","key":"2025081213375222800_ofaf431-B5"},{"key":"2025081213375222800_ofaf431-B6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cir306","article-title":"All-cause, liver-related, and non\u2013liver-related mortality among HCV-infected individuals in the general US population","volume":"53","author":"El-Kamary","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025081213375222800_ofaf431-B7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection-drug users\u2014a hidden danger of the opioid epidemic","volume":"378","author":"Liang","year":"2018","journal-title":"N Engl J Med"},{"key":"2025081213375222800_ofaf431-B8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","article-title":"Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C","volume":"29","author":"Brzd\u0119k","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2025081213375222800_ofaf431-B9","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/liv.14634","article-title":"Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era","volume":"40","author":"Falade-Nwulia","year":"2020","journal-title":"Liver Int"},{"key":"2025081213375222800_ofaf431-B10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","article-title":"Accessible hepatitis C care for people who inject drugs","volume":"182","author":"Eckhardt","year":"2022","journal-title":"JAMA Intern Med"},{"author":"Dearinger","key":"2025081213375222800_ofaf431-B11"},{"author":"US Census Bureau","key":"2025081213375222800_ofaf431-B12"},{"key":"2025081213375222800_ofaf431-B13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CLEP.S43926","article-title":"Socioeconomic status in HCV infected patients\u2014risk and prognosis","volume":"5","author":"Omland","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2025081213375222800_ofaf431-B14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"2025081213375222800_ofaf431-B15","doi-asserted-by":"crossref","first-page":"100748","DOI":"10.1016\/j.jacadv.2023.100748","article-title":"In plain sight: the need for a dedicated cardiovascular infectious disease subspecialty","volume":"3","author":"El-Dalati","year":"2023","journal-title":"JACC Adv"},{"key":"2025081213375222800_ofaf431-B16","doi-asserted-by":"crossref","first-page":"131638","DOI":"10.1016\/j.ijcard.2023.131638","article-title":"Beyond a team: the comprehensive interdisciplinary endocarditis program in the United States","volume":"397","author":"El-Dalati","year":"2024","journal-title":"Int J Cardiol"},{"key":"2025081213375222800_ofaf431-B17","first-page":"20499361241267124","article-title":"Acute drug-use\u2013related native tricuspid valve infective endocarditis: a non-surgical disease","volume":"11","author":"El-Dalati","year":"2024","journal-title":"Ther Adv Infect Dis"},{"key":"2025081213375222800_ofaf431-B18","first-page":"20499361241280690","article-title":"Management of isolated native tricuspid valve infective endocarditis by a multidisciplinary program: a single-center retrospective cohort study","volume":"11","author":"Collis","year":"2024","journal-title":"Ther Adv Infect Dis"},{"key":"2025081213375222800_ofaf431-B19","doi-asserted-by":"crossref","first-page":"ofaf148","DOI":"10.1093\/ofid\/ofaf148","article-title":"Management of cardiovascular implantable electronic device infection utilizing a multidisciplinary team: a retrospective cohort study","volume":"12","author":"Hall","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025081213375222800_ofaf431-B20","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1007\/s11606-023-08386-y","article-title":"Inpatient hepatitis C treatment coordination and initiation for patients who inject drugs","volume":"38","author":"McCrary","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2025081213375222800_ofaf431-B21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/ciad711","article-title":"Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): a stepped wedge cluster randomized trial","volume":"78","author":"Midgard","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025081213375222800_ofaf431-B22","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials","volume":"11","author":"Gane","year":"2021","journal-title":"J Viral Hepat"},{"volume-title":"Epclusa (sofosbuvir and velpatasvir). Package insert","year":"2023","author":"Gilead Sciences, Inc","key":"2025081213375222800_ofaf431-B23"},{"volume-title":"Mavyret (glecaprevir and pibrentasvir). Package insert","year":"2023","author":"AbbVie Inc","key":"2025081213375222800_ofaf431-B24"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf431\/63808444\/ofaf431.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/8\/ofaf431\/63808444\/ofaf431.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/8\/ofaf431\/63808444\/ofaf431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:38:16Z","timestamp":1755020296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf431\/8209542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf431","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,21]]},"article-number":"ofaf431"}}